Number of patients needed to treat during one year to prevent one adverse event
| Number needed to treat (95% confidence interval) | ||||
|---|---|---|---|---|
| In-stent restenosis | In-segment restenosis | TLR | MACE | |
| *95% confidence interval includes benefit and harm (number of patients needed to treat to prevent one event (NNTB); number of patients needed to treat to harm one patient (NNTH)).34 | ||||
| Sirolimus eluting stent | ||||
| Patients without diabetes | 2.4 (2.3 to 2.6) | 2.6 (2.5 to 2.9) | 6.5 (5.9 to 7.6) | 6.2 (5.3 to 8.0) |
| Patients with diabetes | 1.6 (1.5 to 1.9) | 1.9 (1.7 to 2.3) | 5.5 (4.8 to 7.3) | 4.0 (3.4 to 5.5) |
| Paclitaxel eluting stent | ||||
| Patients without diabetes | 3.2 (2.8 to 3.9) | 3.3 (2.9 to 4.0) | 8.1 (7.0 to 10.1) | 16.7 (NNTB 7.7 to NNTH 18.2)* |
| Patients with diabetes | 1.7 (1.5 to 2.3) | 1.7 (1.5 to 2.2) | 5.8 (4.9 to 9.1) | 6.0 (NNTB 3.4 to NNTH 6.3)* |